BPC-157 stability: what 'stable gastric pentadecapeptide' means

Prepared by: Research Desk. Sources are linked for verification.

Read enough BPC-157 papers and one phrase keeps appearing: "stable gastric pentadecapeptide". It sits in titles, abstracts and introductions, often before any data is presented. It is easy to read past the phrase as background, but it is actually a claim. This explainer separates the parts of that label, sets out what kind of stability each part could refer to, and checks what the cited literature does and does not support.

The short version: "stable" is a label used consistently in the titles of papers from a recurring set of authors. A title word is not the same as a pharmaceutical stability profile, and the sources available here contain no independent human data confirming it. For the wider evidence picture, see our evidence guide.

Breaking the label into its parts

Each word in "stable gastric pentadecapeptide" carries a different kind of information.

• Pentadecapeptide is purely structural. It means a chain of 15 amino acids. This part is a chemical description, not a claim about effects.

• Gastric points to the research origin. The label appears in the title of a 2011 review of BPC-157 in the gastrointestinal tract [1], and the stomach and gut are where this literature's naming starts.

• Stable is the interpretive part. The 2011 review places the word directly in its title [1], but a title cannot tell a reader what was measured, in what system, or against what comparison.

So two of the three words are descriptive, and one is an assertion about how the molecule behaves. That third word is where scrutiny belongs.

Three things "stable" could mean

In pharmaceutical science, "stability" is not one property. A paper that calls a molecule stable could be referring to any of the following, and each requires different evidence.

1. Chemical stability

Does the molecule stay intact over time as a substance? This is measured with analytical methods that track purity and the appearance of degradation products. It matters for manufacturing and quality control, and it is the kind of stability regulators ask about.

2. Enzymatic or gastrointestinal stability

Does the molecule survive exposure to digestive fluids and enzymes? As general pharmacology background (not drawn from the sources listed below), short chains of amino acids are typically vulnerable to digestive enzymes, which is why any claim of survival in stomach conditions is notable. Because "stable" sits next to "gastric" in the label [1], this may be the sense intended, but the titles alone do not confirm it.

3. Biological or pharmacokinetic stability

How long does the molecule persist in the body, and in what form? This is measured through pharmacokinetic studies, which track concentrations over time in blood or tissue. Surviving digestive fluid in a test tube would say little on its own about what happens after absorption.

These categories are often blurred in online discussion, where "stable" can drift into implying that a molecule is robust, long-lasting or reliably active. None of those broader meanings follows automatically from a label in a title.

A label that travels across a decade of titles

One way to see how central the phrase has become is to read the titles side by side:

• 2011: a review of BPC-157 in the gastrointestinal tract, titled with "stable gastric pentadecapeptide" [1].

• 2013: a review on toxicity by NSAIDs (common anti-inflammatory painkillers), using the same phrase [2].

• 2021: a review on wound healing, again titled "Stable Gastric Pentadecapeptide BPC 157" [3].

• 2022: a review covering striated, smooth and heart muscle, with the same wording [4].

• 2022: a review on major vessel occlusion and ischemia-reperfusion, which swaps in "cytoprotective" as the leading adjective [5].

These are reviews. Their titles do not state which species or test systems the underlying experiments used, so this page does not characterise them beyond what the titles say; our evidence guide sets out the split between animal and human work. What the list does show is a consistent naming convention. It does not, by itself, show that the stability claim has been re-tested each time, or tested by other laboratories. Repetition in titles and replication of a measurement are different things, and the second is what would settle the question.

The author base is also concentrated. The first authors of these five titles are Sikiric, Seiwerth and Staresinic, names that recur across this literature, with Sikiric leading three of the five [1][2][3][4][5]. When the same overlapping set of authors supplies both the claim and the label, confirmation from unrelated laboratories carries extra weight.

What an outside formulation review signals

A 2026 review in Pharmaceutics describes BPC-157 as an investigational peptide and takes as its subject biopharmaceutical challenges, formulation strategies and translational development barriers [6]. This page does not attribute specific conclusions about BPC-157 degradation to that review. The point is narrower: biopharmaceutical properties and formulation are handled there as topics still worth a dedicated review, rather than as background that can be assumed.

Formulation science deals with the gap between "survives in a test system" and "can be manufactured, characterised and delivered consistently". A molecule can show resilience in one setting and still pose open questions about purity, degradation and behaviour in other conditions.

The regulator's version of the question

FDA approaches stability from a quality and safety angle rather than a mechanistic one. On its list of bulk drug substances that may present significant safety risks in compounding, FDA's entry for BPC-157 records concerns about immunogenicity for certain routes of administration and about complexities with peptide-related impurities and characterisation of the active ingredient [7]. Impurities and characterisation are the regulatory relatives of stability: they ask whether the substance is what it is supposed to be, and whether it stays that way.

FDA's Pharmacy Compounding Advisory Committee held a meeting on 23–24 July 2026 [8]. The dated regulatory record, including approval status, the compounding framework and anti-doping rules, is covered in our legal status file.

What the human literature does and doesn't cover

The human evidence base for BPC-157 is small. A 2025 systematic review examined the emerging use of BPC-157 in orthopaedic sports medicine [9]. A 2026 systematic review assessed human evidence for efficacy and safety in orthopaedic and regenerative medicine [10]. A 2025 pilot study reported on the safety of intravenous infusion in humans [11].

Judging from their stated scope, none of these is a stability or degradation study. Their titles do not indicate that they set out to test whether BPC-157 survives human gastric juice, how long it persists in human blood, or what breakdown products form. In the sources available here, the "stable" label therefore rests on the usage of the authors who coined it, not on a body of independent human pharmacokinetic work.

A reading checklist for "stable" claims

When a paper, article or product page describes BPC-157 as stable, these questions help pin down what is actually being claimed:

1. Which kind of stability? Chemical, gastrointestinal or pharmacokinetic? The word alone does not say.

2. Is there data in this paper, or a citation to earlier work? Many reviews restate a property without new measurements.

3. Who measured it? Results from the originating authors carry less weight until another laboratory reproduces them.

4. In what system? Test tube, rodent or human? Each step changes what the result means.

5. What was the comparison? Stability is relative. A claim is more informative when set against a reference molecule or a degradation threshold.

6. Does it say anything about products sold outside regulated channels? Material characterised in a laboratory is not the same thing as unregulated material, which is exactly the gap FDA's impurity concerns point to [7].

Our About page explains how we label study types and why we always state whether a finding comes from cells, animals or people.

Frequently asked questions

Is BPC-157 proven to be stable in the human stomach?

The word "stable" appears in the titles of papers from the authors who produced much of the early literature [1][2][3][4]. The sources cited here include no independent human study measuring survival in the stomach. It is best read as an author-applied label rather than an established, replicated finding.

Why do so many paper titles include the word "stable"?

It functions as a naming convention used consistently by an overlapping set of authors, appearing in titles from 2011 to 2022 [1][2][3][4]. A recurring label shows consistency of terminology, not repeated measurement.

Does "stable" mean the molecule lasts a long time in the body?

Not necessarily. Survival in digestive fluid is a different property from persistence after absorption, which requires pharmacokinetic studies. Judging from their stated scope, the human reports cited here were not designed to measure either [9][10][11].

Further reading: choosing a biochemistry text

Claims about molecular stability are much easier to judge with a working grasp of protein chemistry: how amide bonds break, how digestive enzymes recognise their targets, and how analytical chemists detect degradation. A good general biochemistry textbook covers all three and earns its shelf space the first time a methods section stops being opaque.

When comparing options, the most useful criteria are concrete: the edition date (enzymology and analytical methods chapters age), whether there are dedicated chapters on protein structure and enzyme kinetics, worked problems with answers, and a reference list that points to primary literature. Format matters too. E-book editions are searchable and often cheaper; print editions are easier for annotating figures.

Price transparency varies widely across academic titles. Older editions frequently cover the core chemistry nearly as well as the newest one at a fraction of the cost, so checking the table of contents against the current edition is worthwhile before paying a premium.

• Accuracy: prefer texts from established academic publishers with named authors and a dated edition.

• Coverage: look for protein structure, enzyme mechanisms and analytical methods in the contents.

• Usability: worked examples, end-of-chapter problems and clear figures.

• Format and cost: compare print, e-book and rental prices for the same edition.

Last updated: 19 October 2026.

Related on this site

• BPC Recover home

• Is BPC-157 legal? FDA, compounding and anti-doping status

• BPC-157: what the evidence actually shows (and doesn't)

• How to evaluate a BPC-157 study: a reader's checklist and reading list

• Sports wearables buyer's guide: GPS watches, chest straps, trackers

• BPC-157 vs TB-500: the evidence and regulatory records compared

• BPC-157 history: where the gastric peptide research came from

• BPC-157 animal studies: what rodent models can and cannot show

• BPC-157 mechanism: the pathways proposed in lab studies

• BPC-157 tendon research: what the rodent studies examined

• Is BPC-157 banned in sport? WADA's prohibited list, explained

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.